Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration
Cochrane Database of Systematic Reviews, 2014•cochranelibrary.com
Background Age‐related macular degeneration (AMD) is the most common cause of
uncorrectable severe vision loss in people aged 55 years and older in the developed world.
Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD‐
related severe vision loss. Anti‐vascular endothelial growth factor (anti‐VEGF) agents,
injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to
prevent vision loss and, in some instances, improve vision. Objectives To investigate:(1) the …
uncorrectable severe vision loss in people aged 55 years and older in the developed world.
Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD‐
related severe vision loss. Anti‐vascular endothelial growth factor (anti‐VEGF) agents,
injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to
prevent vision loss and, in some instances, improve vision. Objectives To investigate:(1) the …
Background
Age‐related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD‐related severe vision loss. Anti‐vascular endothelial growth factor (anti‐VEGF) agents, injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, improve vision.
Objectives
To investigate:(1) the ocular and systemic effects of, and quality of life associated with, intravitreally injected anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) for the treatment of neovascular AMD compared with no anti‐VEGF treatment; and (2) the relative effects of one anti‐VEGF agent compared with another when administered in comparable dosages and regimens.
cochranelibrary.com